Inhibition of human leukocyte elastase by functionalized N-aryl azetidin-2-ones: substituent effects at C-3 and benzylic positions

…, R Kobaiter, R Joyeau, M Wakselman

Index: Zrihen; Labia; Wakselman European Journal of Medicinal Chemistry, 1983 , vol. 18, # 4 p. 307 - 314

Full Text: HTML

Citation Number: 26

Abstract

A series of functionalized N-aryl azetidin-2-ones with a latent alkylating group was prepared by a flexible four-step synthesis. They met criteria expected for a suicide-type inactivation of human leukocyte elastase (HLE) and porcine pancreatic elastase (PPE), with no inactivation

 Related Synthetic Route

~35%

Learn More

~%

Learn More

~82%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~84%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~64%

Learn More

~%

Learn More

~32%

Learn More

~%

Learn More

~53%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~48%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~66%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~94%

Learn More

~%

Learn More

~%

Learn More

~67%

Learn More

~%

Learn More

~%

Learn More

~64%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~88%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~38%

Learn More

~51%

Learn More

~%

Learn More

~81%

Learn More

~%

Learn More

~%

Learn More

~86%

Learn More

~%

Learn More

~%

Learn More

~40%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~99%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~78%

Learn More

~%

Learn More

~%

Learn More

~80%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~71%

Learn More

~%

Learn More

~79%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~78%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~90%

Learn More

~60%

Learn More

~%

Learn More

~76%

Learn More

~60%

Learn More

~%

Learn More

~34%

Learn More

~%

Learn More

~%

Learn More

~45%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~20%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~80%

Learn More

~%

Learn More

~25%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~60%

Learn More

~%

Learn More

~%

Learn More

~58%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~49%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~68%

Learn More

~75%

Learn More

~%

Learn More

~49%

Learn More

~%

Learn More

~92%

Learn More

~%

Learn More

~%

Learn More

~77%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More

~%

Learn More